Roivant Sciences Ltd. (NASDAQ:ROIV - Get Free Report) COO Eric Venker sold 100,000 shares of the stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $11.28, for a total transaction of $1,128,000.00. Following the sale, the chief operating officer now directly owns 732,294 shares in the company, valued at approximately $8,260,276.32. The trade was a 12.01 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Eric Venker also recently made the following trade(s):

ROIV traded down $0.11 during midday trading on Wednesday, hitting $11.16. The company's stock had a trading volume of 3,451,499 shares, compared to its average volume of 4,690,415. Roivant Sciences Ltd. has a 52-week low of $9.69 and a 52-week high of $13.06. The firm has a 50-day moving average price of $11.75 and a two-hundred day moving average price of $11.60. The firm has a market cap of $8.12 billion, a P/E ratio of 1.98 and a beta of 1.27.

Institutional investors and hedge funds have recently bought and sold shares of the stock. Gladius Capital Management LP acquired a new stake in shares of Roivant Sciences in the third quarter worth $35,000. Point72 Hong Kong Ltd purchased a new stake in Roivant Sciences during the 2nd quarter worth $36,000. US Bancorp DE increased its holdings in Roivant Sciences by 146.5% in the 3rd quarter. US Bancorp DE now owns 3,278 shares of the company's stock valued at $38,000 after purchasing an additional 1,948 shares in the last quarter. GAMMA Investing LLC raised its position in Roivant Sciences by 57.0% in the fourth quarter. GAMMA Investing LLC now owns 3,548 shares of the company's stock valued at $42,000 after purchasing an additional 1,288 shares during the period. Finally, Quarry LP acquired a new position in shares of Roivant Sciences during the second quarter worth about $53,000. Institutional investors and hedge funds own 64.76% of the company's stock.

Separately, HC Wainwright restated a "buy" rating and set a $18.00 price target on shares of Roivant Sciences in a report on Wednesday, November 13th. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $17.93.

Read Our Latest Research Report on Roivant Sciences

(Get Free Report)

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Before you consider Roivant Sciences, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Roivant Sciences wasn't on the list.

While Roivant Sciences currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here